Pharvaris price target raised to $38 from $36 at Oppenheimer

Oppenheimer raised the firm’s price target on Pharvaris to $38 from $36 and keeps an Outperform rating on the shares after sitting down with management to discuss recent clinical updates and the path forward for deucrictibant in both on-demand and prophylactic treatment of HAE. The firm came away enthusiastic about the opportunity for Pharvaris’ oral HAE candidate, deucrictibant, as it advances into Phase 3 studies for both indications by year-end.